Small Cap Feast

5th February 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 



Delistings:




Whats baking in the oven?

Potential Initial Public Offerings:

12 January: The London Tunnels PLC announces its intention to seek Admission to the Standard Segment of the Official List and to trading on the Main Market of the LSE. The Company plans to restore, adaptively reuse and bring back to life the Kingsway Exchange Tunnels in Central London, originally built in the early 1940’s, and designed to shelter people during the London Blitz. The Company has successfully raised approximately £10m from investors and aims to admit its Ordinary Shares at a price of £2.00 per share to the Main Market. The Company is expected to have a market capitalisation of approximately £123m on Admission. Delayed: Expected Admission was before the end of January 2024.


Reverse Takeovers:

30 January: Location Sciences Group Plc is proposing to acquire the entire issued share capital of Sorted Holdings Limited (Sorted) for a nominal consideration of £1.00 (Acquisition). Sorted operates a software-as-a-service (SaaS) business model providing delivery experience software which serves ecommerce retailers - from large, global enterprises to smaller, independent start-ups. Pursuant to Rule 14 of the AIM Rules for Companies, the Acquisition constitutes a reverse takeover. Capital to be raised on Admission is approximately £2.0m via a subscription for new Ordinary Shares. Anticipated market capitalisation on Admission is approximately £6.68m. Expected AIM Admission date is 19 February 2024.


Change of Market:


Banquet Buffet

Artemis Resources 0.875p £12.8m (ARV.L)
The gold copper and lithium focused resources Company provide a update on its recent ground reconnaissance program which has resulted in a significant lithium pegmatite discovery at the Mt Marie Lithium Prospect. Ground reconnaissance sampling from 100% owned Artemis Resources tenement E47/1746 delivers positive assay results including: 23AR01-17 - 1.82% Li2O; 23AR01-16 - 1.62% Li2O; 23AR01-15 - 0.78% Li2O. Mineralisation was confirmed by XRD (x-ray diffraction) as being Spodumene. In addition, further work is being planned on the Osborne Lithium Project which is a joint venture with Greentech Metals (ASX:GRE) (ARV:49%-GRE:51%).

Christie Group 87.5p £23.2m (CTG.L)
The group that provides professional services covering surveying, valuation, agency, consultancy, finance, insurance, stock control and software solutions announces that its specialist business property adviser, Christie & Co, has assisted in the merger of two charitable trusts, operating in the social care sector. The Orders of St John Care Trust has announced its merger with The Fremantle Trust, in a transaction where Christie & Co's Care team brokered the combination of the two charities. This transaction illustrates and reinforces Christie & Co's longstanding and established reputation across the UK's social care sector.

EnSilica 48p £39.4m (ENSI.L)
The chipmaker of mixed-signal ASICs (Application Specific Integrated Circuits) announces that it has appointed Kristoff Rademan to the role of Chief Financial Officer. Kristoff will join the Company and Board in May 2024. Kristoff is a finance professional with over twenty years' experience working in corporate finance positions across the pharmaceutical and technology spaces. Kristoff is currently serving as Vice President, Group Financial Controller at Oxford Biomedica Plc. Kristoff previously spent a number of years at European specialty pharmaceutical company, Archimedes Pharma, including a period as the business's UK & Ireland Finance Director.

FireAngel Safety Technology 5.75p £17.4m (FA..L)
The developer and supplier of home safety products provides at trading update on the year ended 31 December 2023. The Group expects to report sales of approximately £41.0m, down 28.8% (2022: £57.5m). Taking into account the net proceeds of £5.3m from the fundraising in June 2023, the Group had £3.1m of net debt as at 31 December 2023 (31 December 2022: £4.8m). With regards to the cash offer by Intelligent Safety Electronics Pte. Ltd (ISE) announced on 27 October 2023, the Offer timetable remains suspended. The Secretary of State has written to ISE and FireAngel on 21 December 2023 issuing a call-in notice under the National Security and Investment Act 2021. The Secretary of State has 30 working days to carry out its assessment and may extend the assessment period by a further 45 working days.

Gaming Realms 37.75p £111.2m (GMR.L)
The developer and licensor of mobile focused gaming content announces its pre-close trading update for the full year to 31 December 2023. The Company expects to report FY23 revenue of c.£23m and adjusted EBITDA of not less than £10.0m, up 23% and 28% respectively year-on-year, in line with Board's expectations. The Company ended the year with £7.5m of net cash. This strong performance has been driven by content licensing, with growth across all major markets. During the year, Gaming Realms went live with a further 44 partners across all its markets.

Gelion plc 19.5p £26.5m (GELN.L)
The Anglo-Australian battery innovator announces the appointment of Dr Louis Adriaenssens as Chief Technological Officer (CTO). Louis joins Gelion with exceptional experience in specialist battery innovation, manufacture and commercialisation, having most recently worked in Nevada as the Supervisor of Chemistry for Panasonic at the Tesla Gigafactory. The appointment of a CTO comes at a pivotal time in the development of Gelion's Lithium-Sulfur and Zinc-based battery technologies and operational expansion into the UK and Europe. This follows the acquisition of OXLiD Ltd in November 2023, whose founder Dr Adrien Amigues will now take up the role of President of Gelion UK and Europe.

Kromek Group 7.55p £45.3m (KMK.L)
The developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments announces that it has been awarded a grant of £1.3m under the UK Research and Innovation Horizon Europe guarantee scheme to participate in the Intelligent Radiation Sensor Readout System (i-RASE) project to develop a new class of radiation sensor powered by artificial intelligence (AI). The i-RASE project, to be led by DTU Space, is a collaboration between industrial and academic partners in Denmark, Germany, Norway and Italy to design, build and test a new class of radiation sensor based on cadmium zinc telluride and other advanced technologies. The project will start on 1 March 2024 and will run for a period of 48 months.

Parkmead Group 16.75p £18.3m (PMG.L)
The independent energy group announced it has been provisionally awarded three new offshore blocks by the North Sea Transition Authority in Tranche 2 of the UK's 33rd Licensing Round awards. This important award consists of a licence covering Blocks 14/15a, 14/20d and 15/11a situated in the Central North Sea. Parkmead will be operator and hold a 50% working interest, alongside its partner Orcadian Energy Limited. The new licence contains seven undeveloped oil discoveries within Mesozoic and Palaeozoic reservoirs. The most substantial of these is Fynn Beauly. The current licence commitment requires no major capital outlay.

Physiomics* 1.45p £2.0m (PYC.L)
The mathematical modelling and data science Company supporting the development of new therapeutics and personalised medicine solutions announces that it has been awarded a further contract by existing client, Numab Therapeutics (Numab). The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in support of one of Numab's oncology assets entering the clinic and will help inform dose and scheduling decisions. Dr Peter Sargent, CEO, commented: "Along with the project we announced with them in August 2023, this new project is testament to the continued support we provide and the great relationships we've built".

Vector Capital 31.5p £14.3m (VCAP.L)
The commercial lending group that offers secured loans to property developers and investors in England & Wales provides a trading update for the year ended 31 December 2023. FY23 revenue is expected to be above market expectations at no less than £5.7m. The Group continues to benefit from its strategic decision to mitigate against default risk by diversifying its portfolio and moving its weighting towards lower-value loans. The aggregate loan book was £48.9m at 31 December 2023, compared with £53.4m at 31 December 2022. At 31 December 2023, the Group had 108 live loans (2022: 107), with an average loan size of approximately £452k (2022: £499k).

5 February 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram